AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

1-Day Seminar: Drafting & Negotiating Clinical Trial Agreements (London, United Kingdom - May 14, 2019) - ResearchAndMarkets.com

May 1, 2019

DUBLIN--(BUSINESS WIRE)--May 1, 2019--The “Drafting and Negotiating Clinical Trial Agreements” conference has been added to ResearchAndMarkets.com’s offering.

Clinical trial agreements are one of the most important agreements in the pharma industry as no research can start without the right agreement in place between sponsor and host organisation. They provide a contract which manages the relationship and responsibilities of both parties, and provide for the allocation of risk, obligations, the protection of academia, terms of collaboration, IP rights and much more.

This intensive one-day programme, delivered by experts in the field, will provide you with a full understanding of the importance of CTAs. It will describe how the regulatory environment affects them and explain the typical clauses which make up a CTA and what the key differences are between European and the US. By the end of this seminar you will be confident in spotting and addressing issues which arise when negotiating and drafting clinical trial agreements.

  • Contract managers
  • Clinical contract specialists
  • Clinical trial managers
  • R&D staff
  • Regulatory specialists
  • Lawyers
  • Legal executives

Agenda

Overview of the legal/policy landscape as it affects the terms of CTAs:

  • What is a clinical trial?
  • EU regulatory framework: What are the key regulatory considerations relevant to conducting a clinical trial?
  • Introduction to the parties to the CTA and key roles and responsibilities
  • Policy issues in public hospitals, e.g. UK NHS approval
  • Other ethical/legal issues
  • Standard contracts, e.g. NHS standard CTA
  • Implications of Brexit

CASE STUDY

Negotiating and drafting CTAs:

  • Overview of issues that frequently come up in the negotiation/drafting of CTAs
  • Introduction to case study
  • Discussion of case study
    • Definitions
    • Intellectual property and publication provisions
    • Use of data generated during the trial
    • Data protection, medical records, freedom of information, etc

CASE STUDY

Negotiating and drafting CTAs - Continued discussion of case study:

  • Manufacture of the investigational medicinal product
  • Warranties and indemnities
  • Liabilities and insurance requirements
  • Termination and its consequences

Additional considerations:

  • Introduction to differences between US, UK and Continental European legal systems and how they may affect contract drafting
  • Unlicensed product vs off-label use
  • First-in-man studies
  • Investigator initiated studies
  • Compliance and anti-corruption issues

PRACTICAL EXERCISE - Negotiation

For more information about this conference visit https://www.researchandmarkets.com/r/6lx8xl

View source version on businesswire.com:https://www.businesswire.com/news/home/20190501005457/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/01/2019 05:38 AM/DISC: 05/01/2019 05:38 AM

http://www.businesswire.com/news/home/20190501005457/en